PROTEASOMES AND EXOSOMES IN OVARIAN CANCER: RALATION WITH DISEASE PROGNOSIS AND CLINICAL OUTCOME
Abstract
The role of circulating proteasomes (C-proteasomes) representing a multisubunit complex with several proteolytically active sites, and exosomes, which are extracellular vesicles providing intracellular and interstitial transfer of biologically important molecules (proteins and miRNAs) in the pathogenesis of ovarian cancer, has been described. Currently, there are prerequisites for further study of the role of C-proteasome and exosome not only as prognostic markers, but also as predictors of the effectiveness of neoadjuvant chemotherapy and optimal cytoreduction.
About the Authors
N. V. Yunusova
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
Russian Federation
I. V. Kondakova
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
Russian Federation
L. А. Kolomiets
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Siberian State Medical University, Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
Russian Federation
5, Kooperativny Street, 634050-Tomsk
S. V. Molchanov
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation
Russian Federation
References
1. Cancer incidence (morbidity and mortality) in Russia in 2010 / Eds. V.I. Chissov, V.V. Starinskij, G.V. Petrova. M., 2012. 260 p. [in Russian]
2. Kondakova I.V., Spirina L.V., Shashova E.E., Koval’ V.D., Kolomiec L.A., Chernyshova A.L., Slonimskaja E.M. Proteasome activity in tumors of the female reproductive system // Bioorganicheskaja himija. 2012. Vol. 38 (1). P. 106–110. [in Russian]
3. Spirina L.V., Kondakova I.V. Role of intracellular specific proteolysis in cancerogenesis // Voprosy onkologii. 2008. № 6. P. 690–694. [in Russian]
4. Spirina L.V., Kondakova I.V., Usynin E.A., Kolomiec L.A., Chojnzonov E.L., Muhamedov M.R., Chernyshova A.L., Sharova N.P. Proteasome activity in cancer tissues // Sibirskij onkologicheskij zhurnal. 2009. № 5. P. 49–52. [in Russian]
5. Shtamm T.A., Naryzhnyj S.N., Landa S.B., Burdakov V.S., Artamonova T.O., Filatov M.V. Isolation and proteomic analysis of exosomes secreted by human cancer cells in vitro // Citologija. 2012. Vol. 54 (5). P. 430–438. [in Russian]
6. Ahmed N., Stenvers K. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research // Front. Oncol. 2013. Vol. 3. Article 256. P. 1–12. doi: 10.3389/fonc.2013.00256.
7. Angioli R., Capriglione S., Aloisi A., Montera R., Luvero D., Miranda A., Cafà E.V., Damiani P., Benedetti-Panici P. Can preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? // Gynecol. Oncol. 2013. Vol. 128 (3). P. 579–583. doi: 10.1016/j.ygyno.2012.11.040.
8. Bookman M.A. Update of randomized trials in first-line treatment // Ann. Oncol. 2011. Vol. 22 (8). Viii. 52–60. doi: 10.1093/annonc/mdr466.
9. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a metaanalysis // Gynecol. Oncol. 2006. Vol. 103. P. 1070–1076.
10. de Martino M., Hoetzenecker K., Ankersmit H.J. Roth G.A., Haitel A., Waldert M., Klatte T. Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis // Br. J. Cancer. 2012. Vol. 106. P. 904–908. doi: 10.1038/bjc.2012.20.
11. Deregibus M.C., Cantaluppi R., Calogero R. et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horisontal transfer of mRNA // Blood. 2007. Vol. 110. P. 81–88.
12. du Bois A., Reuss A., Harter P., Pujade-Lauraine E., Ray-Coquard I., Pfisterer J. Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials // J. Clin. Oncol. 2010. Vol. 28. P. 1733–1739. doi: 10.1200/JCO.2009.25.3617.
13. Graves L.E., Ariztia E.V., Navari J.R., Matzel H.J., Stack M.S., Fishman D.A. Proinvasive properties of ovarian cancer ascites-derived membrane vesicules // Cancer Res. 2004. Vol. 64. P. 7045–7049.
14. Heubner M., Wimberger P., Dahlmann B., Kasimir-Bauer S., Kimmig R., Peters J., Wohlschlaeger J., Sixt S.U. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer // Gynecol. Oncol. 2011. Vol. 120 (2). P. 233–238. doi: 10.1016/j. ygyno.2010.10.014.
15. Hoffmann O., Heubner M., Anlasik T., Winterhalter M.,Dahlmann B., Kasimir-Bauer S., Kimmig R., Wohlschlaeger J., Sixt S.U. Circulating 20S proteasome in patients with non-metastasized breast cancer // Anticancer Res. 2011. Vol. 31 (6). P. 2197–2201.
16. Hynninen J., Auranen A., Dean K., Lavonius M., Carpen O., Perheentupa A., Seppänen M., Grénman S. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer // Int. J. Gynecol. Cancer. 2011. Vol. 21 (9). P. 1573–1578. doi: 10.1097/IGC.0b013e3182225509.
17. Kang S., Kim T.J., Nam B.H. Seo S.S., Kim B.G., Bae D.S., Park S.Y. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis // J. Surg. Oncol. 2010. Vol. 101 (1). P. 13–17. doi: 10.1002/jso.21398.
18. Keller S., Konig A.-K., Marme F., Runz S., Wolterink S.,Koensgen D., Mustea A., Sehouli J., Altevogt P. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes // Cancer Lett. 2009. Vol. 278. P. 73–81. doi: 10.1016/j.canlet.2008.12.028.
19. Kuhlmann J.D., Baraniskin A., Hahn S.A., Mosel F., Bredemeier M., Wimberger P., Kimmig R., Kasimir-Bauer S. Circulating U2 small nuclear fragments as a novel diagnostic tool for patients with epithelial ovarian cancer // Clin. Chem. 2014. Vol. 60. P. 206-13. doi: 10.1373/ clinchem.2013.213066.
20. Lai R.C., Tan S.S., Teh B.J., Sze S.K., Arslan F., de Kleijn D.P., Choo A., Lim S.K. Proteolytic potential of the MSC exosome proteome: implication for an exosome – mediated delivery of the therapeutic proteasome // Int. J. Proteomics. 2012. Vol. 2012. Article ID 971907. doi: 10.1155/2012/971907.
21. Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C. Newly diagnosed and relapsed epithelial ovariancarcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2013. Vol. 24. Suppl. 6. Vi. 24–32. doi: 10.1093/annonc/mdt333.
22. Millimaggi D., Mari M., D’Ascenzo S., Carosa E., Jannini E.A., Zucker S., Carta G., Pavan A., Dolo V. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells // Neoplasia. 2007. Vol. 9. P. 349–357.
23. Mueller O., Anlasik T., Wiedemann J., Thomassen J., Wohlschlaeger J., Hagel V., Keyvani K., Schwieger I., Dahlmann B., Sure U., Sixt S.U. Circulating extracellular proteasome in the cerebrospinal fluid: a study on concentration and proteolytic activity // J. Mol. Neurosci. 2012. Vol. 46 (3). P. 509–515. doi: 10.1007/s12031-011-9631-2.
24. Onda T., Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions // Exp. Rev. Anticancer Ther. 2011. Vol. 11. P. 1053–1067. doi: 10.1586/ era.11.24.
25. Runz S., Kellar S., Rupp C., Stoeck A., Issa Y., Koensgen D., Mustea A., Sehouli J., Kristiansen G., Altevogt P. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM // Gynecol. Oncol. 2007. Vol. 107. P. 563–571.
26. Rupp A.-K., Rupp C., Keller S., Brase J.C., Ehehalt R., Fogel M., Moldenhauer G., Marmé F., Sültmann H., Altevogt P. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage // Gynecol. Oncol. 2011. Vol. 122. P. 437–446. doi: 10.1016/j. ygyno.2011.04.035.
27. Peng P., You Y., Shen K. Isolation, identification and clinical significance of ascites-derived exosomes from patients with ovarian epithelial cancer // Zhonghua Fu Chan Ke Za Zhi. 2009. Vol. 44 (4). P. 268–272.
28. Rodriguez N., Rauch-Hain J.A., Shoni M., Berkowitz R.S., Muto M.G., Feltmate C., Schorge J.O., Del Carmen M.G., Matulonis U.A., Horowitz N.S. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patient with advanced stage ovarian cancer treated with neoadjuvant chemotherapy // Gynecol. Oncol. 2012. Vol. 125 (2). P. 362–366. doi: 10.1016/j.ygyno.2012.02.006.
29. Safaei R., Larson B.J., Cheng T.C. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells // Mol. Cancer Ther. 2005. Vol. 4 (10). P. 1595–1604.
30. Sandri M.T., Bottari F., Franchi D., Boveri S., Candiani M., Ronzoni S., Peiretti M., Radice D., Passerini R., Sideri M. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome // Gynecol. Oncol. 2013. Vol. 128 (2). P. 233–238. doi: 10.1016/j.ygyno.2012.11.026.
31. Sharova N., Zakharova L. Multiple forms of proteasomes and their role in tumor fate // Recent Patents Endocr. Metab. Imm. Drug Discovery. 2008. Vol. 2. P. 152–161.
32. Taylor D.D., Gercel-Taylor C. MicroRNA signature of tumorderived exosomes as diagnostic biomarkers of ovarian cancer // Gynecol. Oncol. 2008. Vol. 110 (1). P. 13–21. doi: 10.1016/j.ygyno.2008.04.033.
33. Weinberg L.E., Rodriguez G., Hurteau J.A. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer // J. Surg. Oncol. 2010. Vol. 101. P. 334–343. doi: 10.1002/jso.21482.
34. Zoeger A., Blau M., Egere K., Feist E., Dahlmann B. Circulating proteasome are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells // Clin. Chem. 2006. Vol. 52 (11). P. 2079–2086.
Review
For citations:
Yunusova N.V., Kondakova I.V., Kolomiets L.А., Molchanov S.V. PROTEASOMES AND EXOSOMES IN OVARIAN CANCER: RALATION WITH DISEASE PROGNOSIS AND CLINICAL OUTCOME. Siberian journal of oncology. 2014;(4):53-59. (In Russ.)
Views:
604
Email this article 
